Erlotinib for Treatment of Psoriasis

NCT01006096 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2014-11-10

No results posted yet for this study

Summary

The purpose of this study is to determine whether erlotinib is effective in the treatment of psoriasis.

Conditions

Interventions

DRUG

erlotinib

100mg tablet, once daily for 16 weeks

OTHER

placebo tablet

placebo tablet (lactose), once daily for 16 weeks

Sponsors & Collaborators

Principal Investigators

  • Anne E Laumann, MBChB, MRCP (UK) · Northwestern University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01006096 on ClinicalTrials.gov